 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM products for cancer will host a Research Development Showcase to provide a comprehensive overview of its CD19 and BCMA programs on November 29, 2022. The Company will also participate in five upcoming investor conferences. 